This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OXFD Oxford Immunotec Global (OXFD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Oxford Immunotec Global Stock (NASDAQ:OXFD) 30 days 90 days 365 days Advanced Chart Get OXFD alerts:Sign Up Key Stats Today's Range$21.99▼$21.9950-Day Range$21.88▼$21.9952-Week Range$8.37▼$23.11VolumeN/AAverage Volume1.10 million shsMarket Capitalization$570.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More… Receive OXFD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter. Email Address OXFD Stock News HeadlinesOxford researchers develop new method of identifying fake Covid-19 vaccinesFebruary 3, 2025 | msn.comA Game-Changing VaccineOctober 30, 2024 | time.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)Oxford Farming Conference announces 2025 Inspire DelegatesOctober 18, 2024 | msn.comNigeria rolls out new Oxford R21 malaria vaccineOctober 18, 2024 | reuters.comUniversity of Oxford scientist addresses UN on tackling antimicrobial resistanceOctober 1, 2024 | msn.comTuberculosis Diagnostics Test Market to hit USD 3.7 billion by 2032, says Global Market Insights Inc.September 24, 2024 | finance.yahoo.comBoat Race: Oxford rowers criticise sewage levels in River ThamesSeptember 16, 2024 | bbc.co.ukSee More Headlines OXFD Stock Analysis - Frequently Asked Questions How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The firm earned $19.44 million during the quarter, compared to analyst estimates of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%. What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO). Company Calendar Last Earnings11/03/2020Today5/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OXFD CIK1586049 Webwww.oxfordimmunotec.com Phone44-0-12-3544-2780FaxN/AEmployees273Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.81 million Net Margins-30.51% Pretax MarginN/A Return on Equity-8.39% Return on Assets-7.63% Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio14.85 Sales & Book Value Annual Sales$73.71 million Price / Sales7.75 Cash Flow$0.02 per share Price / Cash Flow1,408.78 Book Value$8.08 per share Price / Book2.72Miscellaneous Outstanding Shares25,962,000Free FloatN/AMarket Cap$570.90 million OptionableNot Optionable Beta1.42 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:OXFD) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Immunotec Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.